Alimera Sciences

Alimera Sciences (http://investor.alimerasciences.com/), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as http://www.alimerasciences.com/areas-of-focus/diabetic-macular-edema-dme/ (DME), wet and dry http://www.alimerasciences.com/areas-of-focus/age-related-macular-degeneration-amd/ (AMD) and http://www.alimerasciences.com/areas-of-focus/retinal-vein-occlusion-rvo/ (RVO).